Inaticabtagene Autoleucel for Relapsed or Refractory ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of leukemia called B-cell acute lymphoblastic leukemia that has returned or not improved with treatment.
- Your doctor must decide that this treatment is right for you.
- You must agree to take part and sign a consent form, or have a legal guardian sign for you if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This trial tests an engineered immune-cell treatment (GC019F CAR-T) for adults with B-cell ALL that has come back or did not respond to prior therapy. If it works, it may help your immune system attack leukemia cells by targeting CD19.
This study is a long-term follow-up for people who have already received Inaticabtagene Autoleucel, a type of cell therapy. It checks how patients are doing over time, and does not involve any new treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.